{"id":"NCT00712673","sponsor":"Sanofi","briefTitle":"GLP-1 Receptor Agonist Lixisenatide (Morning or Evening) in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin","officialTitle":"A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter 24-week Study Followed by an Extension Assessing the Efficacy and Safety of AVE0010 on Top of Metformin in Patients With Type 2 Diabetes Not Adequately Controlled With Metformin","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-06","primaryCompletion":"2011-03","completion":"2011-03","firstPosted":"2008-07-10","resultsPosted":"2016-12-15","lastUpdate":"2016-12-15"},"enrollment":680,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"Lixisenatide (AVE0010)","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DEVICE","name":"Pen auto-injector","otherNames":["OptiClikÂ®"]},{"type":"DRUG","name":"Metformin","otherNames":[]}],"arms":[{"label":"Lixisenatide (Morning Injection)","type":"EXPERIMENTAL"},{"label":"Lixisenatide (Evening Injection)","type":"EXPERIMENTAL"},{"label":"Placebo (Morning Injection)","type":"PLACEBO_COMPARATOR"},{"label":"Placebo (Evening Injection)","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the benefits and risks of lixisenatide (AVE0010), in comparison to placebo, as an add-on treatment to metformin, over a period of 24 weeks of treatment, followed by an extension.\n\nThe primary objective is to assess the effects of lixisenatide as an add-on treatment to metformin in terms of glycosylated hemoglobin (HbA1c) reduction (absolute change) at Week 24.\n\nThe secondary objectives are to assess the effect of lixisenatide, in comparison to placebo, when administered in the evening within 1 hour prior to the meal in terms of HbA1c reduction, percentage of patients reaching HbA1c less than (\\<) 7 percent (%), percentage of patients reaching HbA1c less than or equal to 6.5%, fasting plasma glucose (FPG), plasma glucose, plasma insulin, C-peptide, glucagon, and proinsulin during a 2-hour standardized meal test (only in morning injection arms), body weight, beta-cell function assessed by homeostasis model assessment (HOMA)-beta, fasting plasma insulin (FPI) and adiponectin; to evaluate safety, tolerability, pharmacokinetics (PK) and anti-lixisenatide antibody development, beta-cell function 4 weeks after study drug discontinuation (only in patients from the morning injection arms in some selected centers).","primaryOutcome":{"measure":"Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24","timeFrame":"Baseline, Week 24","effectByArm":[{"arm":"Placebo (Combined)","deltaMin":-0.38,"sd":0.075},{"arm":"Lixisenatide (Morning Injection)","deltaMin":-0.87,"sd":0.065},{"arm":"Lixisenatide (Evening Injection)","deltaMin":-0.75,"sd":0.066}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"},{"comp":"OG000 vs OG002","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":26},"locations":{"siteCount":16,"countries":["United States","Australia","Canada","Chile","Croatia","Czechia","Germany","Mexico","Morocco","Philippines","Romania","Russia","South Africa","Spain","Ukraine","Venezuela"]},"refs":{"pmids":["23536584","39963952","27319011","27267268"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":85},"commonTop":["Nausea","Headache","Diarrhoea","Nasopharyngitis","Vomiting"]}}